157 related articles for article (PubMed ID: 30544464)
1. Serial measurements of KL-6 for monitoring activity and recurrence of interstitial pneumonia with anti-aminoacyl-tRNA synthetase antibody: A retrospective cohort study.
Yamaguchi K; Iwamoto H; Sakamoto S; Horimasu Y; Masuda T; Miyamoto S; Nakashima T; Ohshimo S; Fujitaka K; Hamada H; Kohno N; Hattori N
Medicine (Baltimore); 2018 Dec; 97(49):e13542. PubMed ID: 30544464
[TBL] [Abstract][Full Text] [Related]
2. Potential of Krebs von den Lungen-6 as a predictor of relapse in interstitial pneumonia with anti-aminoacyl tRNA synthetase antibodies-positive dermatomyositis.
Isoda K; Kotani T; Takeuchi T; Konma J; Ishida T; Hata K; Otani K; Fujiwara H; Shoda T; Makino S; Arawaka S
Clin Respir J; 2018 Jul; 12(7):2235-2241. PubMed ID: 29633527
[TBL] [Abstract][Full Text] [Related]
3. Comparison of long-term prognosis and relapse of dermatomyositis complicated with interstitial pneumonia according to autoantibodies: anti-aminoacyl tRNA synthetase antibodies versus anti-melanoma differentiation-associated gene 5 antibody.
Isoda K; Kotani T; Takeuchi T; Kiboshi T; Hata K; Ishida T; Otani K; Kamimori T; Fujiwara H; Shoda T; Makino S
Rheumatol Int; 2017 Aug; 37(8):1335-1340. PubMed ID: 28451794
[TBL] [Abstract][Full Text] [Related]
4. Association of anti-aminoacyl-transfer RNA synthetase antibody and anti-melanoma differentiation-associated gene 5 antibody with the therapeutic response of polymyositis/dermatomyositis-associated interstitial lung disease.
Yoshida N; Okamoto M; Kaieda S; Fujimoto K; Ebata T; Tajiri M; Nakamura M; Tominaga M; Wakasugi D; Kawayama T; Kuwana M; Mimori T; Ida H; Hoshino T
Respir Investig; 2017 Jan; 55(1):24-32. PubMed ID: 28012490
[TBL] [Abstract][Full Text] [Related]
5. Comparison of cytokine profiles between anti-ARS antibody-positive interstitial lung diseases and those with anti-MDA-5 antibodies.
Asakawa K; Yoshizawa K; Aoki A; Kimura Y; Tanaka T; Ohashi K; Hayashi M; Kikuchi T; Sato S; Takada T
Clin Rheumatol; 2020 Jul; 39(7):2171-2178. PubMed ID: 32056068
[TBL] [Abstract][Full Text] [Related]
6. Evaluation of the Diagnostic Efficacies of Serological Markers KL-6, SP-A, SP-D, CCL2, and CXCL13 in Idiopathic Interstitial Pneumonia.
Xue M; Guo Z; Cai C; Sun B; Wang H
Respiration; 2019; 98(6):534-545. PubMed ID: 31665737
[TBL] [Abstract][Full Text] [Related]
7. Comparison of anti-aminoacyl-tRNA synthetase antibody-related and idiopathic non-specific interstitial pneumonia.
Shioya S; Masuda T; Yamaguchi K; Sakamoto S; Horimasu Y; Nakashima T; Miyamoto S; Senoo T; Iwamoto H; Ohshimo S; Fujitaka K; Hamada H; Hattori N
Respir Med; 2019 Jun; 152():44-50. PubMed ID: 31128609
[TBL] [Abstract][Full Text] [Related]
8. Predictive factors for the recurrence of anti-aminoacyl-tRNA synthetase antibody-associated interstitial lung disease.
Takei R; Yamano Y; Kataoka K; Yokoyama T; Matsuda T; Kimura T; Johkoh T; Takahashi O; Kondoh Y
Respir Investig; 2020 Mar; 58(2):83-90. PubMed ID: 31813784
[TBL] [Abstract][Full Text] [Related]
9. Clinical characteristics of patients with anti-aminoacyl-tRNA synthetase antibody positive idiopathic interstitial pneumonia.
Yura H; Sakamoto N; Satoh M; Ishimoto H; Hanaka T; Ito C; Hasegawa T; Tanaka S; Miyamura T; Nakashima S; Hara A; Kakugawa T; Oda K; Kido T; Obase Y; Ishimatsu Y; Yatera K; Kawakami A; Mukae H
Respir Med; 2017 Nov; 132():189-194. PubMed ID: 29229096
[TBL] [Abstract][Full Text] [Related]
10. Elevated serum Krebs von den Lungen-6 in systemic sclerosis: a marker of lung fibrosis and severity of the disease.
Benyamine A; Heim X; Resseguier N; Bertin D; Gomez C; Ebbo M; Harlé JR; Kaplanski G; Rossi P; Bardin N; Granel B
Rheumatol Int; 2018 May; 38(5):813-819. PubMed ID: 29455320
[TBL] [Abstract][Full Text] [Related]
11. The value of serum Krebs von den lungen-6 as a diagnostic marker in connective tissue disease associated with interstitial lung disease.
Ma H; Lu J; Song Y; Wang H; Yin S
BMC Pulm Med; 2020 Jan; 20(1):6. PubMed ID: 31915006
[TBL] [Abstract][Full Text] [Related]
12. Pulmonary manifestations of anti-ARS antibody positive interstitial pneumonia--with or without PM/DM.
Takato H; Waseda Y; Watanabe S; Inuzuka K; Katayama N; Ichikawa Y; Yasui M; Fujimura M
Respir Med; 2013 Jan; 107(1):128-33. PubMed ID: 23137883
[TBL] [Abstract][Full Text] [Related]
13. Krebs von den Lungen-6 and surfactant protein-A in interstitial pneumonia with autoimmune features.
Xue M; Cai C; Zeng Y; Xu Y; Chen H; Hu H; Zhou L; Sun B
Medicine (Baltimore); 2021 Jan; 100(4):e24260. PubMed ID: 33530214
[TBL] [Abstract][Full Text] [Related]
14. Serum SP-A and KL-6 levels can predict the improvement and deterioration of patients with interstitial pneumonia with autoimmune features.
Wang J; Zheng P; Huang Z; Huang H; Xue M; Liao C; Sun B; Zhong N
BMC Pulm Med; 2020 Dec; 20(1):315. PubMed ID: 33267857
[TBL] [Abstract][Full Text] [Related]
15. Evaluation of changes in the serum levels of Krebs von den Lungen-6 and surfactant protein-D over time as important biomarkers in idiopathic fibrotic nonspecific interstitial pneumonia.
Yamakawa H; Hagiwara E; Ikeda S; Iwasawa T; Otoshi R; Tabata E; Okuda R; Sekine A; Baba T; Iso S; Okudela K; Takemura T; Ogura T
Respir Investig; 2019 Sep; 57(5):422-429. PubMed ID: 31003951
[TBL] [Abstract][Full Text] [Related]
16. Lung ultrasound B-lines and serum KL-6 correlate with the severity of idiopathic inflammatory myositis-associated interstitial lung disease.
Wang Y; Chen S; Lin J; Xie X; Hu S; Lin Q; Zheng K; Du G; Huang X; Zhang G; Gargani L; Matucci-Cerinic M; Furst DE
Rheumatology (Oxford); 2020 Aug; 59(8):2024-2029. PubMed ID: 31794028
[TBL] [Abstract][Full Text] [Related]
17. Diagnostic Value of Krebs von den Lungen (KL-6) for Interstitial Lung Disease: A European Prospective Cohort.
Millan-Billi P; Castellví I; Martinez-Martinez L; Mariscal A; Barril S; D'Alessandro M; Franquet T; Castillo D
Arch Bronconeumol; 2024 Jun; 60(6):350-355. PubMed ID: 38644152
[TBL] [Abstract][Full Text] [Related]
18. Serum KL-6 level is a prognostic marker in patients with anti-MDA5 antibody-positive dermatomyositis associated with interstitial lung disease.
Ye Y; Fu Q; Wang R; Guo Q; Bao C
J Clin Lab Anal; 2019 Oct; 33(8):e22978. PubMed ID: 31301087
[TBL] [Abstract][Full Text] [Related]
19. Comprehensive assessment of myositis-specific autoantibodies in polymyositis/dermatomyositis-associated interstitial lung disease.
Hozumi H; Fujisawa T; Nakashima R; Johkoh T; Sumikawa H; Murakami A; Enomoto N; Inui N; Nakamura Y; Hosono Y; Imura Y; Mimori T; Suda T
Respir Med; 2016 Dec; 121():91-99. PubMed ID: 27888997
[TBL] [Abstract][Full Text] [Related]
20. The long-term outcome of interstitial lung disease with anti-aminoacyl-tRNA synthetase antibodies.
Tanizawa K; Handa T; Nakashima R; Kubo T; Hosono Y; Watanabe K; Aihara K; Ikezoe K; Sokai A; Nakatsuka Y; Taguchi Y; Hatta K; Noma S; Kobashi Y; Yoshizawa A; Oga T; Hirai T; Chin K; Nagai S; Izumi T; Mimori T; Mishima M
Respir Med; 2017 Jun; 127():57-64. PubMed ID: 28461123
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
